Goede, Valentin, Klein, Christian ORCID: 0000-0001-7594-7280 and Stilgenbauer, Stephan (2015). Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkin's Lymphomas: A Glycoengineered Type II CD20 Antibody. Oncol. Res. Treat., 38 (4). S. 185 - 193. BASEL: KARGER. ISSN 2296-5262
Full text not available from this repository.Abstract
Obinutuzumab (GA101) is a humanized, monoclonal type II CD20 antibody modified by glycoengineering. The glycoengineered Fc portion enhances the binding affinity to the Fc gamma RIII receptor on immune effector cells, resulting in increased antibody-dependent cellular cytotoxicity and phagocytosis. In addition, the type II antibody binding characteristics of obinutuzumab to CD20 lead to an efficient induction of direct non-apoptotic cell death. Preclinical data demonstrated more efficient B-cell depletion in whole blood and superior antitumor activity in xenograft models of obinutuzumab as compared to the type I CD20 antibody rituximab. In previously untreated patients with chronic lymphocytic leukemia (CLL) and comorbidities, obinutuzumab plus chlorambucil increased response rates and prolonged progression-free survival compared with rituximab plus chlorambucil. Obinutuzumab had an acceptable and manageable safety profile, with infusion-related reactions during the first infusion as the most common adverse event. Further phase I/II clinical trials have also shown promising activity in other CD20-positive B-cell non-Hodgkin's lymphomas (NHL). Therefore, several clinical studies are planned or ongoing to investigate obinutuzumab with different combination partners in both untreated and relapsed/refractory patients with different B-cell NHL entities, which in addition to CLL include diffuse large B-cell lymphoma and follicular lymphoma.
Item Type: | Journal Article | ||||||||||||||||
Creators: |
|
||||||||||||||||
URN: | urn:nbn:de:hbz:38-408057 | ||||||||||||||||
DOI: | 10.1159/000381524 | ||||||||||||||||
Journal or Publication Title: | Oncol. Res. Treat. | ||||||||||||||||
Volume: | 38 | ||||||||||||||||
Number: | 4 | ||||||||||||||||
Page Range: | S. 185 - 193 | ||||||||||||||||
Date: | 2015 | ||||||||||||||||
Publisher: | KARGER | ||||||||||||||||
Place of Publication: | BASEL | ||||||||||||||||
ISSN: | 2296-5262 | ||||||||||||||||
Language: | English | ||||||||||||||||
Faculty: | Unspecified | ||||||||||||||||
Divisions: | Unspecified | ||||||||||||||||
Subjects: | no entry | ||||||||||||||||
Uncontrolled Keywords: |
|
||||||||||||||||
URI: | http://kups.ub.uni-koeln.de/id/eprint/40805 |
Downloads
Downloads per month over past year
Altmetric
Export
Actions (login required)
View Item |